|Bid||7.39 x 1200|
|Ask||7.40 x 800|
|Day's range||6.85 - 7.44|
|52-week range||3.40 - 9.46|
|Beta (5Y monthly)||0.51|
|PE ratio (TTM)||N/A|
|Earnings date||04 Aug 2021 - 09 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||25.49|
LEIDEN, Netherlands & CAMBRIDGE, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that Company management will present during a fireside chat at the upcoming JMP Securities Life Sciences Conference. The presentation will be webcast live on June 17, 2021, from 3:00 – 3:25pm EDT. The live and archived webcast of the pre
Every investor in ProQR Therapeutics N.V. ( NASDAQ:PRQR ) should be aware of the most powerful shareholder groups...
ProQR (PRQR) delivered earnings and revenue surprises of -7.14% and -92.92%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?